7WOF

SARS-CoV-2 3CLpro

7WOF の概要

• エントリーDOI: 10.2210/pdb7wof/pdb
• 分子名称: 3C-like proteinase, (2S,3S)-3-methyl-N-[(2S)-1-oxidanylidene-3-[(3S)-2-oxidanylidenepiperidin-3-yl]propan-2-yl]-2-[[(E)-3-phenylprop-2-enoyl]amino]pentanamide (3 entities in total)
• 機能のキーワード: sars-cov-2 3clpro, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 34239.06

構造登録者

Wang, Y.,Ye, S. (登録日: 2022-01-21, 公開日: 2022-04-13, 最終更新日: 2024-10-16)

主引用文献

Wang, Y.,Xu, B.,Ma, S.,Wang, H.,Shang, L.,Zhu, C.,Ye, S.
Discovery of SARS-CoV-2 3CL Pro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein-Ligand Interactions.
Int J Mol Sci, 23:-, 2022

PubMed Abstract: As the etiological agent for the coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenges the ongoing efforts of vaccine development and drug design. Due to the accumulating cases of breakthrough infections, there are urgent needs for broad-spectrum antiviral medicines. Here, we designed and examined five new tetrapeptidomimetic anti-SARS-CoV-2 inhibitors targeting the 3C-Like protease (3CL), which is highly conserved among coronaviruses and essential for viral replications. We significantly improved the efficacy of a ketoamide lead compound based on high-resolution co-crystal structures, all-atom simulations, and binding energy calculations. The inhibitors successfully engaged the catalytic dyad histidine residue (H41) of 3CLPro as designed, and they exhibited nanomolar inhibitory capacity as well as mitigated the viral loads of SARS-CoV-2 in cellular assays. As a widely applicable design principle, our results revealed that the potencies of 3CL-specific drug candidates were determined by the interplay between 3CL H41 residue and the peptidomimetic inhibitors.

PubMed: 35216507
DOI: 10.3390/ijms23042392

実験手法

X-RAY DIFFRACTION (1.72 Å)